CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $207,000 | -31.0% | 3,292 | -16.8% | 0.01% | -33.3% |
| Q4 2021 | $300,000 | -18.7% | 3,957 | +20.1% | 0.02% | -25.0% |
| Q3 2021 | $369,000 | -14.0% | 3,295 | +3.1% | 0.03% | -17.6% |
| Q2 2021 | $429,000 | +57.7% | 3,197 | +43.4% | 0.03% | +36.0% |
| Q1 2021 | $272,000 | -49.3% | 2,230 | -36.4% | 0.02% | -50.0% |
| Q4 2020 | $537,000 | +85.2% | 3,507 | +1.2% | 0.05% | +51.5% |
| Q3 2020 | $290,000 | +14.6% | 3,466 | +0.6% | 0.03% | -2.9% |
| Q2 2020 | $253,000 | – | 3,445 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |